Baricitinib

Red

Brand Name(s):Olumiant

Indication:Monogenic interferonopathies

Rationale:1,2,3

Considered:Jul-21

Review Date:Jul-26

Comments:
Baricitinib is recommended to be available as a treatment option through routine commissioning for adults and children 2 years and over with monogenic interferonopathies within the criteria set out in the commissioning policy